RxDoctor Payments Data

Sujeeth Punnam, MD

Cardiovascular Disease · Stockton, CANPI 1932294253

Payments from drug & device makers

$10,296in general payments, 2019–2025

Across 453 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$988
  • Novartis$849
  • Pfizer$614
  • Boehringer Ingelheim$609
  • E.r. Squibb & Sons, L.L.C.$605
  • Johnson & Johnson$588
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$2002%
  • Speaking & faculty fees$2002%
  • Food & beverage$9,72694%
  • Education$1692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,296 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$625,992
Medicare patients
1,535
Services billed
6,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$333,437
EntrestoSacubitril/Valsartan156$160,887
XareltoRivaroxaban141$133,426
JardianceEmpagliflozin45$43,051
MultaqDronedarone Hcl35$42,163
Repatha SureclickEvolocumab55$39,374
BrilintaTicagrelor41$27,041
FarxigaDapagliflozin Propanediol36$21,459
VerquvoVericiguat12$11,347
Metoprolol Succinate298$4,483
Flecainide Acetate98$4,227
Ezetimibe81$3,318
Atorvastatin Calcium321$3,172
ClopidogrelClopidogrel Bisulfate243$2,836
Losartan Potassium244$2,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$614$333,437329 claims
NovartisEntresto$849$160,887156 claims
Johnson & JohnsonXarelto$588$133,426141 claims
AstraZenecaBrilinta, Farxiga$480$48,50077 claims
Boehringer IngelheimJardiance$609$43,05145 claims
Sanofi-aventis U.S. LLCMultaq$464$42,16335 claims
MerckVerquvo$456$11,34712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →